D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 7, 2019 Category: Drugs & Pharmacology Source Type: news
Medical News Today: What are protease inhibitors for HIV?
Protease inhibitors are a class of HIV medication. They block the function of HIV protease enzymes. Taken with other antiretroviral drugs, protease inhibitors help prevent HIV from multiplying. Brand names include Reyataz, Prezista, and Lexiva. Learn about the actions and side effects of protease inhibitors here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news
Dual Therapy Lets HIV Patients Avoid Problem Drugs
(MedPage Today) -- Dolutegravir plus boosted darunavir an option for people avoiding NRTIs (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 10, 2018 Category: Infectious Diseases Source Type: news
Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Tablets) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 25, 2018 Category: Drugs & Pharmacology Source Type: news
FDA Approves Symtuza (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
TITUSVILLE, N.J, JULY 17, 2018 – The Janssen Pharmaceutical Companies of Johnson& Johnson today announced the U.S. Food and Drug Administration (FDA) has approved Symtuza (darunavir, cobicistat, emtricitabine and tenofovir alafenamide -... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 17, 2018 Category: Drugs & Pharmacology Source Type: news
Janssen Announces U.S. FDA Approval of SYMTUZA ™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen
for the Treatment of HIV-1 Infection
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2018 Category: Pharmaceuticals Source Type: news
Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen
for the Treatment of HIV-1 Infection
(Source: Johnson and Johnson)
Source: Johnson and Johnson - July 17, 2018 Category: Pharmaceuticals Source Type: news
Increased Risk of Cardiovascular Disease With Darunavir Increased Risk of Cardiovascular Disease With Darunavir
Cumulative use of ritonavir-boosted darunavir, a contemporary protease inhibitor used to treat HIV, is associated with an increasing risk of cardiovascular disease, according to results from the D:A:D study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - May 22, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Doravirine Effective in Treatment-naive Adults With HIV Doravirine Effective in Treatment-naive Adults With HIV
Doravirine, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), is as effective as ritonavir-boosted darunavir, a protease inhibitor, in treatment-naive adults infected with HIV-1, according to results from the DRIVE-FORWARD trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 12, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Hetero launches FDC combination of key HIV drugs
The FDC drug ‘Darunavir+Ritonavir’ is an anti-retroviral medication indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adult patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 14, 2017 Category: Pharmaceuticals Source Type: news
Single-Pill HIV Regimen Scores in New Patients Single-Pill HIV Regimen Scores in New Patients
A new single-tablet regimen with boosted darunavir and tenofovir alafenamide works in virally suppressed HIV patients, AMBER trial results confirm, but when should it be tried in the treatment na ï ve?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 3, 2017 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
Investigational Darunavir-Based Single-Tablet Regimen Shows Positive Results in Previously Untreated HIV Patients in Pivotal Phase 3 AMBER Clinical Trial
AMBER 48-week safety and efficacy results to be presented at the 16th European AIDS Conference (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 25, 2017 Category: Pharmaceuticals Source Type: news
Single-tablet Switch Option Effective in Virologically Suppressed HIV Single-tablet Switch Option Effective in Virologically Suppressed HIV
A new single-tablet regimen (STR) that includes the protease inhibitor (PI) darunavir, cobicistat, emtricitabine, and tenofovir alafenamide maintains viral suppression in adults infected with HIV-1, according to results from the EMERALD phase 3 noninferiority trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 20, 2017 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
